Literature DB >> 15921811

Economic burden of post-acute myocardial infarction heart failure in the United Kingdom.

L Lacey1, M Tabberer.   

Abstract

Congestive heart failure (CHF) is a major cause of morbidity and mortality. This study was carried out to quantify the burden of CHF, subsequent to acute myocardial infarction (AMI), from the perspective of the UK National Health Service (NHS). A systematic literature review of publications since 1990 was carried out on the economic burden of heart failure. The economic burden of post-AMI heart failure in the UK for the year 2000 was estimated for two scenarios: (1) Base-case estimate (post-AMI heart failure accounts for 20% of heart failure cases): Direct healthcare costs of pound 125-181 million (approx. 0.4% of total NHS spend) and nursing home costs of pound 27 million; (2) Upper estimate (post-AMI heart failure accounts for 50% of the total): Direct healthcare costs of pound 313-453 million (approx 1.0% of total NHS spend) and nursing home costs of pound 68 million. In conclusion, post-AMI heart failure imposes a significant direct economic burden on the UK.

Entities:  

Mesh:

Year:  2005        PMID: 15921811     DOI: 10.1016/j.ejheart.2004.10.020

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  11 in total

Review 1.  Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.

Authors:  Greg L Plosker; Susan J Keam
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 2.  Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.

Authors:  Katherine F Croom; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Prophylactic amiodarone and lidocaine improve survival in an ovine model of large size myocardial infarction.

Authors:  Tieluo Li; Xufeng Wei; A Claire Watkins; Pablo G Sanchez; Zhongjun J Wu; Bartley P Griffith
Journal:  J Surg Res       Date:  2013-06-07       Impact factor: 2.192

Review 4.  Roles of melatonin and its receptors in cardiac ischemia-reperfusion injury.

Authors:  Kodchanan Singhanat; Nattayaporn Apaijai; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Cell Mol Life Sci       Date:  2018-08-13       Impact factor: 9.261

5.  Effect of wenxin granule on ventricular remodeling and myocardial apoptosis in rats with myocardial infarction.

Authors:  Aiming Wu; Jianying Zhai; Dongmei Zhang; Lixia Lou; Haiyan Zhu; Yonghong Gao; Limin Chai; Yanwei Xing; Xiying Lv; Lingqun Zhu; Mingjing Zhao; Shuoren Wang
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-13       Impact factor: 2.629

6.  Direct and indirect costs of COPD progression and its comorbidities in a structured disease management program: results from the LQ-DMP study.

Authors:  Florian Kirsch; Anja Schramm; Larissa Schwarzkopf; Johanna I Lutter; Boglárka Szentes; Manuel Huber; Reiner Leidl
Journal:  Respir Res       Date:  2019-10-10

7.  Patients with coronary artery disease after acute myocardial infarction: effects of continuous enrollment in a structured Disease Management Program on adherence to guideline-recommended medication, health care expenditures, and survival.

Authors:  Florian Kirsch; Christian Becker; Anja Schramm; Werner Maier; Reiner Leidl
Journal:  Eur J Health Econ       Date:  2020-02-01

8.  Effects of adherence to pharmacological secondary prevention after acute myocardial infarction on health care costs - an analysis of real-world data.

Authors:  Florian Kirsch; Christian Becker; Christoph Kurz; Lars Schwettmann; Anja Schramm
Journal:  BMC Health Serv Res       Date:  2020-12-20       Impact factor: 2.655

9.  Melatonin as a therapy in cardiac ischemia-reperfusion injury: Potential mechanisms by which MT2 activation mediates cardioprotection.

Authors:  Kodchanan Singhanat; Nattayaporn Apaijai; Thidarat Jaiwongkam; Sasiwan Kerdphoo; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  J Adv Res       Date:  2020-09-28       Impact factor: 10.479

10.  Potential economic consequences of a cardioprotective agent for patients with myocardial infarction: modelling study.

Authors:  Talitha I Verhoef; Stephen Morris; Anthony Mathur; Mervyn Singer
Journal:  BMJ Open       Date:  2015-11-13       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.